Top Markets
Coin of the day
Cardiol Therapeutics Inc. Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc.

CRDL
Clasificación en acciones #17188
Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company,... Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship product, CardiolRx, is currently undergoing a significant Phase II/III international clinical trial. This extensive study is randomized, double-blind, and placebo-controlled, evaluating CardiolRx's efficacy and safety as a heart-protective therapy to mitigate cardiovascular and respiratory issues in individuals hospitalized with COVID-19. Concurrently, the trial also assesses CardiolRx's role in addressing acute myocarditis. Beyond this, the company is developing an injectable, subcutaneous formulation of CardiolRx, intended to target cardiac scarring and inflammation that contribute to the development and worsening of heart failure. Established in 2017, Cardiol Therapeutics Inc. is based in Oakville, Canada.
Precio por acción
$2.17
Capitalización bursátil
$249.58M
Cambio (1 día)
-1.67%
Cambio (1 año)
96.34%
País
CA
Comercio Cardiol Therapeutics Inc. (CRDL)

Categoría

Historial de rendimiento por dividendo de Cardiol Therapeutics Inc. (CRDL)
Rendimiento por dividendo (TTM) de Cardiol Therapeutics Inc. (símbolo bursátil: CRDL) al 2026: 0
Rendimiento promedio por dividendo de los últimos 5 años: 0.00%
Historial de rendimiento por dividendo de Cardiol Therapeutics Inc. (CRDL) desde 2026 hasta 2026
Rendimiento por dividendo al final de cada año (TTM)
Año Rendimiento por dividendo Cambiar
Not enough data for the provided dates.
Rendimientos por dividendo (TTM) de empresas similares o competidoras